For more information, visit: [ Ссылка ] In this webinar, we present a new method of PBMC isolation from clinical or non-clinical blood samples: automated, standardized, and without the need for density gradient centrifugation.
In order to minimize sample variation and ensure the quality of PBMCs, the Gutenberg COVID-19 cohort study used this method to generate pure and viable PBMCs from over 20,000 blood samples, allowing investigation of not only the direct effects of SARS-CoV-2 infection and COVID-19 disease progression, but also the comprehensive effects of the pandemic, and the measures to fight it, on the health of the population.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
